title: Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.
abstract: Pathophysiology of hallucinations in Parkinson's disease is poorly understood. This study investigated relationships between visual hallucinations and visual acuity. Twenty-six consecutive patients with Parkinson's disease participated in this study. Patients were divided into two groups: patients with visual hallucinations (VH group) and those without visual hallucinations (no-VH group). Unaided and corrected eyesight was evaluated in all patients, and if frequent use of prescription glasses or contact lenses was involved, eyesight using these lenses was also measured as the patient's own best eyesight. If a patient did not use prescription glasses or contact lenses, the patient's own best eyesight was defined as the unaided eyesight. Multivariate regression analysis demonstrated that agonist use and best eyesight were different after the backward elimination method. Visual hallucinations were closely related not to uncorrected eyesight or unaided eyesight but to the patient's best eyesight. It is suggested that impaired visual acuity is a risk factor for visual hallucinations.
authors.affiliation: Department of Neurology, Sumitomo Hospital, Osaka, Japan. matsui-hideaki@sumitomo-hp.or.jp
authors.forename: Hideaki
authors.initials: H
authors.lastname: Matsui
authors.forename: Fukashi
authors.initials: F
authors.lastname: Udaka
authors.forename: Akiko
authors.initials: A
authors.lastname: Tamura
authors.forename: Masaya
authors.initials: M
authors.lastname: Oda
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Kubori
authors.forename: Kazuto
authors.initials: K
authors.lastname: Nishinaka
authors.forename: Masakuni
authors.initials: M
authors.lastname: Kameyama
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006212:Hallucinations / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000523:psychology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis* / Q000523:psychology; D012044:Regression Analysis; D012307:Risk Factors; D013223:Statistics as Topic; D014787:Vision Tests; D014792:Visual Acuity
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa